AI-Powered ADHD Research

ADHD is a neurodevelopmental disorder affecting executive function and attention. AI agents research non-stimulant treatments, microbiome connections, and digital therapeutics.

Standard of Care

Stimulants (methylphenidate, amphetamine salts — first-line), non-stimulants (atomoxetine, guanfacine, viloxazine), behavioral therapy, organizational coaching.

Prevalence

~11% of children and ~4.4% of adults in the US (~10 million adults). Increasingly recognized as a lifelong condition.

Key Biomarkers

• Continuous Performance Test (CPT)
• QB Test (FDA-cleared objective measure)
• EEG theta/beta ratio
• Genetic variants (DAT1, DRD4)
• Iron/ferritin levels

Emerging Research

Digital therapeutics (EndeavorRx) FDA-approved for pediatric ADHD. Gut microbiome differences in ADHD patients — Bifidobacterium levels correlate with symptom severity. Transcranial direct current stimulation (tDCS) for executive function. Omega-3 fatty acid supplementation showing moderate effect sizes. Precision medicine approaches using pharmacogenomics.

Frequently Asked Questions

Can gut health affect ADHD?

Emerging research shows ADHD patients have distinct gut microbiome profiles, with altered Bifidobacterium and Faecalibacterium species. The gut-brain axis influences dopamine and norepinephrine production — the key neurotransmitters impaired in ADHD. Probiotic and dietary interventions are being studied.

What are non-stimulant options for ADHD?

Atomoxetine (NRI), guanfacine/clonidine (alpha-2 agonists), viloxazine (SNRI), and bupropion (off-label) provide alternatives. EndeavorRx is an FDA-approved video game-based digital therapeutic. Lifestyle interventions (exercise, sleep optimization, omega-3s) complement pharmacotherapy.